| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_98aabec4b0dece2b6b797747ec6127b7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-321
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-20 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-907
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-65522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-102
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-88
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-34 |
| filingDate |
2020-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b72e3539dd0698bed5b6d6ecdf11e389
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1bbd85b7547f115411395ab505ca39c8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8192edeb4f1893bbe80fa6f022357855
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27ef1cf81d242b36e7fe04fba2d3c11a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_260c6009f7d0b88bd9beea4021884f99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3efd00d1062215dc3fc2e5b428f49d0 |
| publicationDate |
2021-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2020318916-A1 |
| titleOfInvention |
Stabilized CRISPR complexes |
| abstract |
Provided herein are polynucleotides and CRISPR effector proteins configured to be covalently bound together in a CRISPR complex. The polynucleotides can be further modified to modulate the activity of the CRISPR complex. Modification of the polynucleotide and CRISPR effector protein can be used to improve the efficacy of target binding and/or cleavage. |
| priorityDate |
2019-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |